Overview

Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID

Status:
Completed

Trial end date:
2009-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating presence or absence of gastric and/or duodenal ulcers throughout the treatment period (24 weeks) in terms of efficacy on prevention of gastric and/or duodenal ulcers

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Anti-Inflammatory Agents, Non-Steroidal
Esomeprazole